These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 25433242)

  • 1. Ceftibuten-induced filamentation of extended spectrum beta lactamase (ESBL)-producing uropathogenic Escherichia coli alters host cell responses during an in vitro infection.
    Demirel I; Kruse R; Önnberg A; Persson K
    Microb Pathog; 2015 Jan; 78():52-62. PubMed ID: 25433242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of host response mechanisms evoked by extended spectrum beta lactamase (ESBL)--and non-ESBL-producing uropathogenic E. coli.
    Demirel I; Kinnunen A; Onnberg A; Söderquist B; Persson K
    BMC Microbiol; 2013 Aug; 13():181. PubMed ID: 24059789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiresistant uropathogenic extended-spectrum β-lactamase (ESBL)-producing Escherichia coli are susceptible to the carbon monoxide releasing molecule-2 (CORM-2).
    Bang CS; Kruse R; Demirel I; Onnberg A; Söderquist B; Persson K
    Microb Pathog; 2014 Jan; 66():29-35. PubMed ID: 24361394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended-spectrum β-lactamase/AmpC-producing uropathogenic Escherichia coli from HIV patients: do they have a low virulence score?
    Padmavathy K; Padma K; Rajasekaran S
    J Med Microbiol; 2013 Mar; 62(Pt 3):345-351. PubMed ID: 23161767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftibuten plus amoxicillin-clavulanic acid for oral treatment of urinary tract infections with ESBL producing E. coli and K. pneumoniae: a retrospective observational case-series.
    Cohen Stuart J; Leverstein-Van Hall M; Kortmann W; Verlind J; Mulder F; Scharringa J; Fluit A; Ekkelenkamp M
    Eur J Clin Microbiol Infect Dis; 2018 Oct; 37(10):2021-2025. PubMed ID: 30117050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended spectrum β-lactamase producing uropathogenic Escherichia coli and the correlation of biofilm with antibiotics resistance in Nepal.
    Shrestha R; Khanal S; Poudel P; Khadayat K; Ghaju S; Bhandari A; Lekhak S; Pant ND; Sharma M; Marasini BP
    Ann Clin Microbiol Antimicrob; 2019 Dec; 18(1):42. PubMed ID: 31847837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Fosfomycin susceptibility of urinary Escherichia coli isolates producing extended-spectrum beta-lactamase according to CLSI and EUCAST recommendations].
    Cağan Aktaş S; Gençer S; Batırel A; Hacıseyitoğlu D; Ozer S
    Mikrobiyol Bul; 2014 Oct; 48(4):545-55. PubMed ID: 25492650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lower prevalence of hlyD, papC and cnf-1 genes in ciprofloxacin-resistant uropathogenic Escherichia coli than their susceptible counterparts isolated from southern India.
    Harwalkar A; Gupta S; Rao A; Srinivasa H
    J Infect Public Health; 2014; 7(5):413-9. PubMed ID: 24861644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections.
    Azap OK; Arslan H; Serefhanoğlu K; Colakoğlu S; Erdoğan H; Timurkaynak F; Senger SS
    Clin Microbiol Infect; 2010 Feb; 16(2):147-51. PubMed ID: 19689464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative susceptibility of clinical isolates producing extended spectrum beta-lactamases to ceftibuten: effect of large inocula.
    Medeiros AA; Crellin J
    Pediatr Infect Dis J; 1997 Mar; 16(3 Suppl):S49-55. PubMed ID: 9076836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and Antibiotic Susceptibility Patterns of Extended-Spectrum ß-Lactamase and Metallo-ß-Lactamase-Producing Uropathogenic Escherichia coli Isolates.
    Ghadiri H; Vaez H; Razavi-Azarkhiavi K; Rezaee R; Haji-Noormohammadi M; Rahimi AA; Vaez V; Kalantar E
    Lab Med; 2014; 45(4):291-6. PubMed ID: 25316659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotypic and Genotypic Characteristics of Uropathogenic
    Muriuki CW; Ogonda LA; Kyanya C; Matano D; Masakhwe C; Odoyo E; Musila L
    Microb Drug Resist; 2022 Jan; 28(1):31-38. PubMed ID: 34297634
    [No Abstract]   [Full Text] [Related]  

  • 13. The antibacterial effect of nitric oxide against ESBL-producing uropathogenic E. coli is improved by combination with miconazole and polymyxin B nonapeptide.
    Bang CS; Kinnunen A; Karlsson M; Önnberg A; Söderquist B; Persson K
    BMC Microbiol; 2014 Mar; 14():65. PubMed ID: 24629000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular characterization of beta-lactamase genes produced by community-acquired uropathogenic Escherichia coli in Nouna.
    Kiemde D; Ribeiro I; Sanou S; Coulibaly B; Sie A; Ouedraogo AS; Souares A; Eibach D
    J Infect Dev Ctries; 2020 Nov; 14(11):1274-1280. PubMed ID: 33296340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial resistance, multilocus sequence types and virulence profiles of ESBL producing and non-ESBL producing uropathogenic Escherichia coli isolated from cats and dogs in Switzerland.
    Zogg AL; Zurfluh K; Schmitt S; Nüesch-Inderbinen M; Stephan R
    Vet Microbiol; 2018 Mar; 216():79-84. PubMed ID: 29519530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergence of co-production of plasmid-mediated AmpC beta-lactamase and ESBL in cefoxitin-resistant uropathogenic Escherichia coli.
    Ghosh B; Mukherjee M
    Eur J Clin Microbiol Infect Dis; 2016 Sep; 35(9):1449-54. PubMed ID: 27250633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clonal groups of extended-spectrum β-lactamase and biofilm producing uropathogenic
    Qasemi A; Rahimi F; Katouli M
    Pathog Glob Health; 2022 Dec; 116(8):485-497. PubMed ID: 34904540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clonal Relatedness, Phylotyping and Antimicrobial Susceptibility of Extended- spectrum-beta-lactamase Producing Uropathogenic Escherichia coli Isolates from Outpatients and Inpatients.
    Azimzadeh N; Derakhshandeh A; Motamedifar M; Naziri Z
    Infect Disord Drug Targets; 2020; 20(5):659-666. PubMed ID: 31322075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of uropathogenic ESBL-producing Escherichia coli isolated from hospitalized patients in western Algeria.
    Zenati F; Barguigua A; Nayme K; Benbelaïd F; Khadir A; Bellahsene C; Bendahou M; Hafida H; Timinouni M
    J Infect Dev Ctries; 2019 Apr; 13(4):291-302. PubMed ID: 32045373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ESBL-producing uropathogenic Escherichia coli isolated from dogs and cats in Switzerland.
    Huber H; Zweifel C; Wittenbrink MM; Stephan R
    Vet Microbiol; 2013 Mar; 162(2-4):992-996. PubMed ID: 23177909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.